Tyra Biosciences (TYRA) Invested Capital (2020 - 2026)

Tyra Biosciences has reported Invested Capital for 7 years, with the latest figure at $387.6 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 19.79% year-over-year to $387.6 million; the trailing twelve-month figure through Mar 2026 stood at $387.6 million (up 19.79% YoY), and the FY2025 full-year result was $259.2 million, down 24.47% from the prior year.
• Invested Capital for Q1 2026 stood at $387.6 million, up from $259.2 million in the prior quarter.
• The five-year high for Invested Capital was $389.9 million in Q1 2024, with the low at $204.3 million in Q4 2023.
• Historically, Invested Capital has averaged $296.1 million across 5 years, with a median of $280.5 million in 2025.
• Annual changes were most pronounced in 2022 — Invested Capital surged 1761.82% — and 2025, when it retreated 24.47%.
• Tyra Biosciences' Invested Capital stood at $257.8 million in 2022, then declined by 20.78% to $204.3 million in 2023, then soared by 68.0% to $343.2 million in 2024, then slipped by 24.47% to $259.2 million in 2025, then jumped by 49.54% to $387.6 million in 2026.
• The last three Invested Capital figures came in at $387.6 million (Q1 2026), $259.2 million (Q4 2025), and $280.5 million (Q3 2025), per Business Quant data.